Titanovo Logo
Back to Cell Types

SK-N-ASHomo sapiens (Human)Cancer cell line

Also known as: SKNAS, SKN-AS, SK-NA-S

🤖 AI SummaryBased on 14 publications

Quick Overview

Human neuroblastoma cell line used in cancer research.

Detailed Summary

The SK-N-AS cell line is a human neuroblastoma cell line derived from a bone marrow metastasis of a 6-year-old female patient with non-MYCN-amplified neuroblastoma. It is widely used in research for studying neuroblastoma biology, drug resistance, and therapeutic strategies. This cell line has been utilized in multiple studies to investigate genetic alterations, such as those involving the ALK and RET receptors, and has been adapted to study resistance to various chemotherapeutic agents, including oxaliplatin. Additionally, it has been employed in studies examining the role of cell polarity genes and their disruption in cancer progression. The cell line is also used to explore the effects of targeted therapies and to understand the molecular mechanisms underlying neuroblastoma development and progression.

Research Applications

Neuroblastoma biologyDrug resistance mechanismsGenetic alterations (ALK, RET)Chemotherapy resistance (oxaliplatin)Cell polarity gene disruptionTargeted therapy development

Key Characteristics

Non-MYCN-amplifiedOxaliplatin-resistant sub-line availableUsed in multiple cancer research studies
Generated on 6/17/2025

Basic Information

Database IDCVCL_1700
SpeciesHomo sapiens (Human)
Tissue SourceBone marrow[UBERON:UBERON_0002371]

Donor Information

Age6
Age CategoryPediatric
SexFemale
Racecaucasian

Disease Information

DiseaseNeuroblastoma
LineagePeripheral Nervous System
SubtypeNeuroblastoma
OncoTree CodeNBL

DepMap Information

Source TypeATCC
Source IDACH-000260_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleNRASp.Gln61Lys (c.181C>A)UnspecifiedAcquired during resistance selection processPubMed=26214590

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10,12
D13S317
9
D16S539
14
D18S51
14,15
D19S433
12,14
D21S11
32.2,33.2
D2S1338
17,24
D3S1358
14
D5S818
11,12
D7S820
11,13
D8S1179
13,14
FGA
20,22
Penta D
9
Penta E
7,14
TH01
9.3
TPOX
11,12
vWA
16,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

Loss of RET promotes mesenchymal identity in neuroblastoma cells.";

Van den Eynden J., Hallberg B., Palmer R.H., Guan J.-K.

Cancers (Basel) 13:1909.1-1909.25(2021).

DOIPubMedPMC

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

DOIPubMed

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways.

Hallberg B.

Sci. Signal. 11:eaar5680.1-eaar5680.16(2018).

DOIPubMed

Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.

Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.

Sci. Data 4:170033-170033(2017).

DOIPubMedPMC

Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS.

Michaelis M.

PLoS ONE 12:E0172140-E0172140(2017).

DOIPubMedPMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOIPubMed

Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired resistance to a broad range of drugs.

Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.

Transl. Oncol. 6:685-696(2013).

DOIPubMedPMC

Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.

Vogelstein B., Kinzler K.W., Velculescu V.E., Hogarty M.D.

Nat. Genet. 45:12-17(2013).

DOIPubMedPMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.

Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.

Int. J. Cancer 131:1556-1568(2012).

DOIPubMedPMC

NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.

Messiaen L.M., Versteeg R., Bernards R.

Cell 142:218-229(2010).

DOIPubMedPMC

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOIPubMedPMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOIPubMedPMC

Identification of ALK as a major familial neuroblastoma predisposition gene.

Maris J.M.

Nature 455:930-935(2008).

DOIPubMedPMC

Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.

Puisieux A.

Mol. Cancer 7:50.1-50.12(2008).

DOIPubMedPMC

Identification of side population cells (stem-like cell population) in pediatric solid tumor cell lines.

Hayashi Y.

J. Pediatr. Surg. 42:2040-2045(2007).

DOIPubMed

1H MRS identifies specific metabolite profiles associated with MYCN-amplified and non-amplified tumour subtypes of neuroblastoma cell lines.

Edwards E.C., Strachan M.C., McMullan D.J., Wilkes T.M., Grundy R.G.

NMR Biomed. 20:692-700(2007).

DOIPubMed

Mutations in PIK3CA are infrequent in neuroblastoma.";

Dam V., Morgan B.T., Mazanek P., Hogarty M.D.

BMC Cancer 6:177.1-177.10(2006).

DOIPubMedPMC

High-resolution detection and mapping of genomic DNA alterations in neuroblastoma.

Maris J.M.

Genes Chromosomes Cancer 43:390-403(2005).

DOIPubMed

PPM1D is a potential target for 17q gain in neuroblastoma.";

Sugimoto T., Inazawa J.

Cancer Res. 63:1876-1883(2003).

PubMed

Mutations of the BRAF gene in human cancer.";

Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Nature 417:949-954(2002).

DOIPubMed

Combined M-FISH and CGH analysis allows comprehensive description of genetic alterations in neuroblastoma cell lines.

Salwen H.R., Laureys G., Manoel N., De Paepe A., Speleman F.

Genes Chromosomes Cancer 32:126-135(2001).

DOIPubMed

Comparative genomic hybridization analysis of human neuroblastomas: detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines.

De Paepe A., Cremer T., Speleman F.

Cancer Genet. Cytogenet. 97:135-142(1997).

DOIPubMed

Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification.

Speleman F., Versteeg R.

Oncogene 10:291-297(1995).

PubMed

Determination of cell surface membrane antigens common to both human neuroblastoma and leukemia-lymphoma cell lines by a panel of 38 monoclonal antibodies.

Minowada J.

J. Natl. Cancer Inst. 73:51-57(1984).

DOIPubMed

Human neuroblastoma cells and 13-cis-retinoic acid.";

Helson L., Helson C.

J. Neurooncol. 3:39-41(1985).

DOIPubMed

Vitamin E and human neuroblastoma.";

Helson L., Verma M., Helson C.

(In book chapter) Modulation and mediation of cancer by vitamins; Meyskens F.L., Prasad K.N. (eds.); pp.258-265; Karger; Basel; Switzerland (1983).

DOI

Tumor cell lines of the peripheral nervous system.";

Israel M.A., Thiele C.J.

(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York; USA (1994).

DOI

Neuroblastoma.";

Thiele C.J.

(In book chapter) Human cell culture. Vol. 1. Cancer cell lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York; USA (1999).

DOI

Web Resources

cells-talk.comthermofisher.com